Compare CF Industries Holdings, Inc. (CF) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CF Industries Holdings, Inc. vs Crispr Therapeutics AG — how do they compare? CF Industries Holdings, Inc. trades at $117.73 (market cap $17.83B), while Crispr Therapeutics AG trades at $53.93 (market cap $5.23B). The key difference: CF Industries Holdings, Inc. is far larger — about 3.4× Crispr Therapeutics AG's market cap, and CF Industries Holdings, Inc. pays a 2.04% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CF | CRSP | |
|---|---|---|
Market Cap | $17.83B | $5.23B |
Sector | Basic Materials | Health |
52-Week High | $137.55 | $76.78 |
52-Week Low | $76.08 | $44.34 |
Enterprise Value | $18.96B | $3.65B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CF Industries Holdings (CF) trades at $117.57, down 3.25% today, with a bearish technical signal. The stock shows strong profitability with a 27.12% net margin and a low P/E of 8.74, indicating potential undervaluation. Recent Q2 2026 earnings missed estimates but revenue grew 17.6% year-over-year, supported by strong nitrogen pricing. The company maintains solid cash flow, with net cash flow turning positive to $368 million in 2025 after two years of negatives.
The outlook is mixed; robust fundamentals and a consensus price target of $119.60 suggest upside, but near-term headwinds include volatile fertilizer demand and execution risks from operational issues like the Yazoo City outage. Long-term growth is supported by tight global nitrogen supply conditions into 2027.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
